Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: Systematic review

Heart

Volumn 100, Issue 6, 2014, Pages 465-472

  Guttmann, Oliver P ^a   Rahman, M Shafiqur ^b   O'Mahony, Constantinos ^a   Anastasakis, Aris ^c   Elliott, Perry M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF DHAKA   (Bangladesh)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT;

AGE; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INCIDENCE; LEFT ATRIAL DIAMETER; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SINUS RHYTHM; SYSTEMATIC REVIEW; THROMBOEMBOLISM;

ATRIAL FIBRILLATION; CARDIOMYOPATHY, HYPERTROPHIC; HUMANS; INCIDENCE; PREVALENCE; RISK FACTORS; THROMBOEMBOLISM; WORLD HEALTH;

EID: 84896722136     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-304276     Document Type: Article

References (42)

1. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults : echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation 1995;92:785-9.
2. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004;363: 1881-91. (Pubitemid 38748646)
3. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62: e1-34.
4. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. (Pubitemid 17189972)
5. Ho HH, Lee KL, Lau CP, et al. Clinical characteristics of and long-term outcome in Chinese patients with hypertrophic cardiomyopathy. Am J Med 2004; 116:19-23. (Pubitemid 38050022)
6. Shigematsu Y, Hamada M, Mukai M, et al. Mechanism of atrial fibrillation and increased incidence of thromboembolism in patients with hypertrophic cardiomyopathy. Jpn Circ J 1995;59:329-36.
7. Cecchi F, Montereggi A, Olivotto I, et al. Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy assessed by signal averaged P wave duration. Heart 1997;78:44-9. (Pubitemid 27346880)
8. Ozdemir O, Soylu M, Demir AD, et al. P-wave durations as a predictor for atrial fibrillation development in patients with hypertrophic cardiomyopathy. Int J Cardiol 2004;94:163-6. (Pubitemid 38490654)
9. Kubo T, Kitaoka H, Okawa M, et al. Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy. Results from Kochi RYOMA Study. Circ J 2009;73:1599-605.
10. Ogimoto A, Hamada M, Nakura J, et al. Relation between angiotensin-converting enzyme II genotype and atrial fibrillation in Japanese patients with hypertrophic cardiomyopathy. J Hum Genet 2002;47:184-9. (Pubitemid 34496178)
11. Robinson K, Frenneaux MP, Stockins B, et al. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol 1990;15:1279-85. (Pubitemid 20141104)
12. Tani T, Tanabe K, Ono M, et al. Left atrial volume and the risk of paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2004;17:644-8. (Pubitemid 38858042)
13. Doi Y, Kitaoka H. Hypertrophic cardiomyopathy in the elderly: significance of atrial fibrillation. J Cardiol 2001;37(Suppl 1):133-8.
14. Maron BJ, Olivotto I, Bellone P, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:301-7. (Pubitemid 34084637)
15. Losi MA, Betocchi S, Aversa M, et al. Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy. Am J Cardiol 2004;94:895-900. (Pubitemid 39359175)
16. Higashikawa M, Nakamura Y, Yoshida M, et al. Incidence of ischemic strokes in hypertrophic cardiomyopathy is markedly increased if complicated by atrial fibrillation. Jpn Circ J 1997;61:673-81.
17. Cecchi F, Olivotto I, Montereggi A, et al. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995;26:1529-36.
18. Spirito P, Lakatos E, Maron BJ. Degree of left ventricular hypertrophy in patients with hypertrophic cardiomyopathy and chronic atrial fibrillation. Am J Cardiol 1992;69:1217-22.
19. Nagai T, Ogimoto A, Okayama H, et al. A985G polymorphism of the endothelin-2 gene and atrial fibrillation in patients with hypertrophic cardiomyopathy. Circ J 2007;71:1932-6. (Pubitemid 350261419)
20. Yamaji K, Fujimoto S, Yutani C, et al. Does the progression of myocardial fibrosis lead to atrial fibrillation in patients with hypertrophic cardiomyopathy? Cardiovasc Pathol 2001;10:297-303. (Pubitemid 34076464)
21. Gruver EJ, Fatkin D, Dodds GA, et al. Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta-cardiac myosin heavy chain mutation. Am J Cardiol 1999;83:13H-8H. (Pubitemid 29330922)
22. Olivotto I, Cecchi F, Casey SA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001;104:2517-24. (Pubitemid 33107372)
23. Yang WI, Shim CY, Kim YJ, et al. Left atrial volume index: a predictor of adverse outcome in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2009;22:1338-43.
24. Maron BJ, Casey SA, Poliac LC, et al. Clinical course of hypertrophic cardiomyopathy in a Regional United States Cohort. JAMA 1999;281:650-5. (Pubitemid 29098067)
25. Kose S, Aytemir K, Sade E, et al. Detection of patients with hypertrophic cardiomyopathy at risk for paroxysmal atrial fibrillation during sinus rhythm by P-wave dispersion. Clin Cardiol 2003;26:431-4. (Pubitemid 37072058)
26. Bunch TJ, Chandrasekaran K, Ehrsam JE, et al. Prognostic significance of exercise induced arrhythmias and echocardiographic variables in hypertrophic cardiomyopathy. Am J Cardiol 2007;99:835-8. (Pubitemid 46365606)
27. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000;102:858-64.
28. Moon J, Shim CY, Ha JW, et al. Clinical and echocardiographic predictors of outcomes in patients with apical hypertrophic cardiomyopathy. Am J Cardiol 2011;108:1614-19.
29. Papavassiliu T, Germans T, Fluchter S, et al. CMR findings in patients with hypertrophic cardiomyopathy and atrial fibrillation. J Cardiovasc Magn Reson 2009;11:34.
30. Tani T, Yagi T, Kitai T, et al. Left atrial volume predicts adverse cardiac and cerebrovascular events in patients with hypertrophic cardiomyopathy. Cardiovasc Ultrasound 2011;9:34.
31. Lee CH, Liu PY, Lin LJ, et al. Clinical features and outcome of patients with apical hypertrophic cardiomyopathy in Taiwan. Cardiology 2006;106:29-35.
32. Pedrosa RP, Drager LF, Genta PR, et al. Obstructive sleep apnea is common and independently associated with atrial fibrillation in patients with hypertrophic cardiomyopathy. Chest 2010;137:1078-84.
33. Kitaoka H, Kubo T, Okawa M, et al. Left ventricular remodeling of hypertrophic cardiomyopathy: longitudinal observation in rural community. Circ J 2006;70:1543-9. (Pubitemid 44819867)
34. Shigematsu Y, Hamada M, Nagai T, et al. Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy: association with insulin resistance. J Cardiol 2011;58:18-25.
35. Cecchi F, Olivotto I, Betocchi S, et al. The Italian Registry for hypertrophic cardiomyopathy: a nationwide survey. Am Heart J 2005;150:947-54. (Pubitemid 41607773)
36. Lee CH, Liu PY, Lin LJ, et al. Clinical characteristics and outcomes of hypertrophic cardiomyopathy in Taiwan-a tertiary center experience. Clin Cardiol 2007;30:177-82.
37. Maron BJ, Casey SA, Haas TS, et al. Hypertrophic cardiomyopathy with longevity to years or older. Am J Cardiol 2012;109:1341-7
38. Soliman OI, Knaapen P, Geleijnse ML, et al. Assessment of intravascular and extravascular mechanisms of myocardial perfusion abnormalities in obstructive hypertrophic cardiomyopathy by myocardial contrast echocardiography. Heart 2007;93:1204-12. (Pubitemid 47492903)
39. Di Donna P, Olivotto I, Delcre SD, et al. Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. Europace 2010;12:347-55.
40. Bunch TJ, Munger TM, Friedman PA, et al. Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2008;19:1009-14.
41. Kilicaslan F, Verma A, Saad E, et al. Efficacy of catheter ablation of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. Heart Rhythm 2006;3:275-80. (Pubitemid 43264402)
42. Gaita F, Di Donna P, Olivotto I, et al. Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy. Am J Cardiol 2007;99:1575-81. (Pubitemid 46773025)